Timothy A. Springer, Director, 10% Owner at Cartesian Therapeutics, Inc. (RNAC), bought 16,032 shares at $12.72 ($204K) on 2024-08-12, disclosed to the SEC on 2024-08-14.
Open-market purchase of $204k RNAC by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.72 | 8,016 | $102K | 50.0% |
| 2 | $12.72 | 8,016 | $102K | 50.0% |
| Total | $12.72 avg | 16,032 | $204K | 100% |
| Filing → |
| TECX | BUY | 2025-04-09 | $17.1M | — | Filing → |
| RNAC | BUY | 2025-03-20 | $2.7M | — | Filing → |
| TECX | BUY | 2025-02-07 | $47.0M | — | Filing → |